Shares of Evolus (EOLS +35.84%) climbed on Wednesday after the aesthetics specialist announced that it achieved profitability. By the close of trading, Evolus' stock price was up over 35%. The path to profitEvolus' products can soften wrinkles and temporarily improve the appearance of frown lines in adults. Demand for the beauty company's offerings is rising, with revenue growing 14% year over year to $90.3 million in the fourth quarter. Moreover, customers appear to be satisfied with the results, with reor ...

At 7:15 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hi ...

分组1 - Evolus, Inc. reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.01 per share a year ago [1] - The company posted revenues of $90.3 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.98% and up from $78.95 million year-over-year [2] - Evolus shares have declined approximately 35.5% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Evolus is uncertain, with current consensus EPS estimates at -$0.11 for the coming quarter and -$0.04 for the current fiscal year, alongside revenues of $71.74 million and $330.94 million respectively [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 41% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Evolus was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Evolus (NasdaqGM:EOLS) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAlyssa Peri - Equity Research AssociateDavid Moatazedi - President and CEONareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications.Rui Avelar - CMO and Head of Research and DevelopmentTatiana Mitchell - CFOConference Call ParticipantsAnnabel Samimy - Managing Director and Senior AnalystDoug Tsao - Managing Director of Equity Research and Senior Healthcare AnalystNavann Ty - Stock Analys ...

Evolus (NasdaqGM:EOLS) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAlyssa Peri - Equity Research AssociateDavid Moatazedi - President and CEONareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications.Rui Avelar - CMO and Head of Research and DevelopmentTatiana Mitchell - CFOConference Call ParticipantsAnnabel Samimy - Managing Director and Senior AnalystDoug Tsao - Managing Director of Equity Research and Senior Healthcare AnalystNavann Ty - Stock Analys ...

Evolus (NasdaqGM:EOLS) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Speaker5Good afternoon, everyone, thank you for standing by. Welcome to Evolus' fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, today's conference call is being recorded and webcast live. All participants are in a listen-only mode, after the speakers' remarks, there'll be a question-and- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________ FORM 10-K _____________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 _____________________________ EVOLUS, INC. (Exact name of registrant as speci ...

INVESTOR PRESENTATION MARCH 2026 2 This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and product candidates; the potential market ...

Core Viewpoint - Evolus, Inc. (EOLS) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings per share (EPS) estimated at $0.06, reflecting a 500% increase, and revenues projected at $89.42 million, up 13.3% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to be released on March 3, and the stock price may rise if the actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Evolus is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.33%, suggesting a bullish outlook from analysts [12]. - However, the stock holds a Zacks Rank of 4, complicating the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Evolus was expected to post a loss of $0.19 per share but delivered a smaller loss of -$0.14, resulting in a positive surprise of +26.32% [13]. - Over the past four quarters, Evolus has only beaten consensus EPS estimates once [14]. Industry Context - Perrigo (PRGO), a peer in the Zacks Medical - Products industry, is expected to report an EPS of $0.8 for the same quarter, indicating a year-over-year decline of 14%, with revenues projected at $1.1 billion, down 3.2% from the previous year [18].

Core Insights - Evolus, Inc. (NASDAQ:EOLS) has had its price target lowered by Mizuho analyst Uy Ear from $19 to $15 while maintaining an Outperform rating, indicating confidence in the company's long-term growth despite a weaker-than-expected fourth quarter [1] - The company reported a revenue of $69 million for the third quarter of 2025, reflecting a 13% year-over-year growth, driven by strong demand for its products Jeuveau and Evolysse [3] - Evolus focuses on injectable aesthetic treatments in the cash-pay market and aims to expand its international presence while building a differentiated portfolio of physician-led brands [4] Financial Performance - The revenue of Evolus for the third quarter of 2025 was $69 million, marking a 13% increase compared to the previous year [3] - The growth is attributed to sustained global demand for Jeuveau and the U.S. launch of Evolysse, showcasing the company's ability to diversify its revenue streams [3] Company Strategy - Evolus is positioning itself for continued market share gains by expanding its product portfolio and international footprint [4] - The company was founded in 2012 and is headquartered in Newport Beach, California, indicating a relatively young but strategically focused operation in the performance beauty sector [4]